Molecular aspects of breast cancer resistance to drugs (Review)

dc.creatorCalaf, Gloria M.
dc.creatorZepeda, Andrea B.
dc.creatorCastillo Peñaloza, Rodrigo
dc.creatorFigueroa, Carolina A.
dc.creatorArias, Consuelo
dc.creatorFigueroa, Elías
dc.creatorFarías, Jorge G.
dc.date.accessioned2015-10-08T19:26:57Z
dc.date.accessioned2019-04-26T00:30:18Z
dc.date.available2015-10-08T19:26:57Z
dc.date.available2019-04-26T00:30:18Z
dc.date.created2015-10-08T19:26:57Z
dc.date.issued2015
dc.identifierInternational Journal of Oncology Volumen: 47 Número: 2 Aug 2015
dc.identifierDOI: 10.3892/ijo.2015.3055
dc.identifierhttp://repositorio.uchile.cl/handle/2250/134289
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/2438520
dc.description.abstractDespite continuous advances in the knowledge of breast cancer pathophysiology, this type of neoplasia remains a leading cause of cancer-related death in women worldwide. Carcinogenesis takes a progressive course from somatic mutations, alteration of the DNA repair mechanisms, inhibition of growth suppressors, followed by cell proliferation, tissue invasion and risk of metastasis. Less than 10% of all cancers are hereditary, and in the case of breast cancer only 8%, a phenomenon linked to genetic changes in BRCA1 or BRCA2. All the other cancers can be caused by an infection (15%) or in most cases (75%) the etiology is unknown. Patients with genetic mutations in BRCA1 or BRCA2 have 30-60% likelihood of developing a second primary breast cancer and between 11 and 45% risk of ovarian cancer, HER-2/neu is overexpressed in similar to 30% of human breast tumors and it has a predictive role in chemotherapy and endocrine therapy.
dc.languageen
dc.publisherSpandidos Publ
dc.subjectBreast cancer
dc.subjectMultidrug resistance
dc.subjectCancer classifications
dc.titleMolecular aspects of breast cancer resistance to drugs (Review)
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución